Fda has granted veru a pre-emergency use authorization (eua) meeting date for positive sabizabulin phase 3 covid-19 study

Miami, may 02, 2022 (globe newswire) -- veru inc. (nasdaq: veru), a biopharmaceutical company, today announced that the fda has granted the company a pre-emergency use authorization (eua) meeting on may 10, 2022, for the positive phase 3 covid-19 study for sabizabulin.
VERU Ratings Summary
VERU Quant Ranking